1. Phase II Dose Selection for Alpha Synuclein–Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain. (19th August 2020) Authors: Kuchimanchi, Mita; Monine, Michael; Kandadi Muralidharan, Kumar; Woodward, Caroline; Penner, Natalia Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 9:Number 9(2020) Page Start: 515 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054. Issue 8 (17th June 2019) Authors: Brys, Miroslaw; Fanning, Laura; Hung, Serena; Ellenbogen, Aaron; Penner, Natalia; Yang, Minhua; Welch, Mackenzie; Koenig, Erica; David, Eric; Fox, Tara; Makh, Shavy; Aldred, Jason; Goodman, Ira; Pepinsky, Blake; Liu, YuTing; Graham, Danielle; Weihofen, Andreas; Cedarbaum, Jesse M. Journal: Movement disorders Issue: Volume 34:Issue 8(2019) Page Start: 1154 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗